New pharmacotherapy options for noninfectious posterior uveitis

Area of Science:

• Ophthalmology
• Rheumatology
• Immunology

Background:

• Noninfectious posterior uveitis causes significant visual impairment, particularly in younger individuals.
• Traditional treatments like steroids and nonbiologic Disease-Modifying Antirheumatic Drugs (nbDMARDs) are being supplemented by newer biologic agents.
• The personal and social impact of this condition necessitates exploring advanced therapeutic options.

Purpose of the Study:

• To review recent therapeutic advancements in noninfectious posterior segment uveitis.
• To identify emerging treatment strategies beyond conventional therapies.

Main Methods:

• A comprehensive literature search was performed using keywords such as nbDMARD, bDMARD, posterior uveitis, intermediate uveitis, treatment, and corticosteroid.
• Clinical studies registered on ClinicalTrials.gov were also included.

Main Results:

• Current treatment paradigms include intraocular anti-inflammatory agents and novel systemic therapies like biologic Disease-Modifying Antirheumatic Drugs (bDMARDs) and small-molecule inhibitors.
• Intravitreal treatments minimize systemic side effects, while new systemic agents demonstrate increasing therapeutic efficacy.
• Biologic DMARDs are gaining prominence for their effectiveness in managing noninfectious posterior uveitis.

Conclusions:

• Despite limitations in randomized controlled trials, significant progress is evident in the treatment of noninfectious posterior uveitis.
• Ongoing research and development continue to yield promising therapeutic advancements.
• Novel biologic agents represent a significant step forward in managing this vision-impairing condition.